We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals

52 hedge funds and large institutions have $108M invested in Fennec Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

29% more capital invested

Capital invested by funds: $83.8M → $108M (+$24M)

1.56% more ownership

Funds ownership: 54.54%56.1% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less funds holding

Funds holding: 5552 (-3)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
52
Holders Change
-3
Holders Change %
-5.45%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
8
Increased
20
Reduced
12
Closed
10
Calls
$12K
Puts
Net Calls
+$12K
Net Calls Change
-$127K
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
26
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$151K +$16.2K +2,132 +15%
Bank of America
27
Bank of America
North Carolina
$150K -$3.75K -493 -2%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$149K +$12.2K +1,600 +9%
AQR Capital Management
29
AQR Capital Management
Connecticut
$124K -$39.4K -5,168 -24%
Deutsche Bank
30
Deutsche Bank
Germany
$123K +$32.8K +4,302 +35%
SO
31
STRS Ohio
Ohio
$115K
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$86K -$63.2K -8,300 -42%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$85K -$164K -21,492 -65%
Invesco
34
Invesco
Georgia
$75K +$77.2K +10,133 New
JP Morgan Chase
35
JP Morgan Chase
New York
$72K +$12.9K +1,699 +21%
Barclays
36
Barclays
United Kingdom
$53K -$21.2K -2,779 -28%
TRCT
37
Tower Research Capital (TRC)
New York
$36K -$121K -15,937 -77%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$31.4K -$7.59K -997 -19%
Citigroup
39
Citigroup
New York
$30K +$23.7K +3,113 +303%
UBS Group
40
UBS Group
Switzerland
$26K +$27K +3,550 New
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$25K +$18.2K +2,388 +237%
Legal & General Group
42
Legal & General Group
United Kingdom
$20K
AIP
43
Ameritas Investment Partners
Nebraska
$14K
Simplex Trading
44
Simplex Trading
Illinois
$14K +$14.1K +1,853 +1,732%
Nisa Investment Advisors
45
Nisa Investment Advisors
Missouri
$11K +$11.4K +1,500 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$9K +$7.91K +1,039 +626%
PS
47
Planned Solutions
California
$6K +$6.09K +800 New
Group One Trading
48
Group One Trading
Illinois
$2K +$2.41K +317 New
QCG
49
Quadrant Capital Group
Ohio
$1K +$602 +79 New
AIG
50
American International Group
New York
$94 -$1.02K -134 -1%

FENC Hedge Fund Activity: Q4 2020 in Review

52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2020, worth a combined $108M — up 29% from $83.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FENC and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 20 added.

The largest buyer was Sonic Fund II, adding an estimated $6.08M. The largest seller was Wedbush Securities, exiting entirely with an estimated $417K sold.

  • 52 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2020, down from 55 in Q3 2020.
  • Funds reported $108M of Fennec Pharmaceuticals stock for Q4 2020, up 29% quarter-over-quarter.
  • 8 funds opened new Fennec Pharmaceuticals positions in Q4 2020 and 10 closed out, a net change of -2 holders.
  • The largest Fennec Pharmaceuticals buyer in Q4 2020 was Sonic Fund II, an estimated $6.08M added.
  • The largest Fennec Pharmaceuticals seller in Q4 2020 was Wedbush Securities, an estimated $417K sold.

Based on aggregated 13F filings for Q4 2020.